Merck

MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour

Retrieved on: 
Wednesday, April 17, 2024
Education, Science, Other Science, Primary, Secondary, Merck Group, Sigma-Aldrich, Student, Transformation, Multimedia, Merck, Tourism

MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.

Key Points: 
  • MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.
  • View the full release here: https://www.businesswire.com/news/home/20240417283942/en/
    MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour (Photo: Business Wire)
    “Recent data shows students between 8 and 13 years old are interested in science and math, with most calling these subjects fun and exciting.
  • Students also meet our employees, who can be role models for the incredible range of STEM careers that are possible.”
    For the 2024 tour, the Curiosity Cube is sporting a new look, displaying photos of young scientists who are children of MilliporeSigma employees.
  • To learn more about the Curiosity Cube mobile science lab and view the 2024 tour schedule, visit TheCuriosityCube.com and follow the Curiosity Cube on Instagram @curiositycube_milliporesigma.

MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Pharmaceutical, Health, FDA, Merck Group, Investment, Risk, Sigma-Aldrich, Software suite, Automation, Multimedia, GMP, Merck

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
  • The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.
  • The Aptegra™ platform transforms biosafety testing with a digital solution using next-generation sequencing.”
    Currently, FDA guidance requires biotech companies to use multiple assays to address genetic stability requirements.
  • Its global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Retrieved on: 
Tuesday, April 16, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Janus, Third Rock Ventures, Cancer, SCCHN, Cell, Neck, Pembrolizumab, Merck & Co., Infection, Immunotherapy, PD-1, AstraZeneca, Patient, Wellington Management Company, Renal cell carcinoma, RCC, Melanoma, Head, Toxicity, Bristol Myers Squibb, Merck, NSCLC, Autoimmunity, NK, Lung cancer, Vaccine

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
  • “We are delighted to have the continued support of RA Capital, and excited to add two top biopharmaceutical companies and experts in oncology to our investor syndicate,” said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • We are pleased to have investors with deep and hands-on expertise in the cytokine space recognizing our early clinical data and our differentiated approach.
  • Initial pharmacokinetic and pharmacodynamic data from the ongoing Phase 1a/1b clinical trial support AB248’s proof of mechanism and activity with a highly differentiated clinical profile.

Parenteral Drug Association and Euromed Communications Release Second Co-published book, Industrial Pharmaceutical Microbiology: Quality Control

Retrieved on: 
Wednesday, April 24, 2024
Education, Parenteral Drug Association, Sterility, Merck & Co., PDA, Science, Patient, Multimedia, Control, Merck, Quality control, Pharmaceutical industry

BETHESDA, Md., April 24, 2024 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and UK-based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Quality Control. This 500-page book includes 20 chapters from 19 industry leaders in pharmaceutical microbiology quality control. Electronic copies are sold on both publishers' bookstores for $299.00. Hardcopies can be purchased for $340 at Euromed Communication's website.

Key Points: 
  • BETHESDA, Md., April 24, 2024 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and UK-based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Quality Control.
  • This 500-page book includes 20 chapters from 19 industry leaders in pharmaceutical microbiology quality control.
  • Industrial Pharmaceutical Microbiology: Quality Control is an in-depth, comprehensive survey of quality control methods in the pharmaceutical microbiology laboratory to enable better understanding and to ensure better developed, more compliant, expedited procedures.
  • Parenteral Drug Association (PDA) is the leading global provider of science, technology, and regulatory information.

GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target

Retrieved on: 
Wednesday, April 24, 2024
Antigen presentation, AACR, Therapy, Genomics, Merck, IGSF8, NK, Neoplasm, AI, Vaccine

CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.

Key Points: 
  • CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
  • Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune evasion and resistance to cancer immunotherapy, whereas how tumors evade innate immunity is less clear.
  • In this study, the authors discovered that tumors with antigen presentation defects over express IGSF8 which interacts with NK receptors to suppress NK cell cytotoxicity.
  • These results support IGSF8 as a novel innate immune checkpoint that could be exploited as a therapeutic target, and led to the nomination of GV20's lead program, GV20-0251.

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Wednesday, April 24, 2024
MSD, FDA, Clinical trial, BJHM, Safety, AI, Neutropenia, Merck & Co., Pembrolizumab, Innovation, Tumor microenvironment, PD-L1, Obesity, Hanmi Pharmaceutical, Patient, Principal, KOSPI, Drug development, Merck, MASH, TME, Pharmaceutical industry

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, 'BH3120', in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with progressive or metastatic solid tumors.
  • Hanmi Pharmaceutical will sponsor the clinical trial, and MSD will supply KEYTRUDA.
  • 'BH3120' is a next-generation immunotherapy drug that applies 'Pentambody', a bispecific antibody platform technology, currently under joint development by Hanmi Pharmaceutical and its Chinese subsidiary, BJHM (Beijing Hanmi Pharmaceutical).
  • He said, "Through the collaboration with MSD, we expect BH3120 in combination with KEYTRUDA could improve outcomes for patients with relapsed or refractory disease."

Touch Taiwan 2024 Showcases Smart Cockpit, Micro LED, and AI Opportunities

Retrieved on: 
Monday, April 22, 2024
AI, Shin-Etsu Chemical, Business, MicroLED, ASRG, Society for Information Display, Exhibition, Conference, Semiconductor, FANUC, Professional corporation, Merck, Delta, SIEMENS, USB On-The-Go, Yole, TPSA, International, Smart manufacturing, AWS, AUO, Somatosensory system, Coherence, MITSUBISHI, Panel, Electronic, Oxford Instruments

TAIPEI, April 22, 2024 /PRNewswire/ -- Touch Taiwan 2024, the leading display technology exhibition in Asia, will be held from April 24 to 26 at the Taipei Nangang Exhibition Hall, Taipei, Taiwan.

Key Points: 
  • TAIPEI, April 22, 2024 /PRNewswire/ -- Touch Taiwan 2024, the leading display technology exhibition in Asia, will be held from April 24 to 26 at the Taipei Nangang Exhibition Hall, Taipei, Taiwan.
  • Organized by Taiwan Display Union Association (TDUA), Taiwan Panel & Solution Association (TPSA), Taiwan Display Materials & Devices Association (TDMDA), Taiwan Electronic Equipment Industry Association (TEEIA), Society for Information Display (SID) and Chan Chao Int'l Co., Ltd.
  • The Smart Display Zone will focus on smart cockpits, Micro LED, and field applications.
  • With the surge of AI and 5G, this year's concurrent "Smart Manufacturing Exhibition" focuses on AI and digital transformation.

Catalyst Welcomes Northrop Grumman CEO Kathy Warden as New Board Chair

Retrieved on: 
Thursday, April 18, 2024
BK, Woman, General Electric, Aerospace Industries Association, Operational excellence, Grumman, Merck & Co., Chairperson, Central Waqf Council, Workplace, History, SAIC, Northrop Grumman, General Dynamics, Merck, Greater Washington Partnership, Accenture, Disability, Chair, Management

NEW YORK, April 18, 2024 /PRNewswire/ -- Catalyst, a global nonprofit promoting gender equity and workplace inclusion, has named Kathy Warden, CEO of Northrop Grumman Corporation, Chair of its Board. She succeeds Accenture CEO Julie Sweet and is the fourth woman to chair the Board.  

Key Points: 
  • Three New Members from Deloitte, SAIC and Genpact Also Join the Catalyst Board
    NEW YORK, April 18, 2024 /PRNewswire/ -- Catalyst , a global nonprofit promoting gender equity and workplace inclusion, has named Kathy Warden, CEO of Northrop Grumman Corporation, Chair of its Board.
  • "Stepping into this important role and building on Catalyst's more than 60-year history of strengthening gender equity in the workplace is truly a privilege," said Kathy Warden, Chair, CEO and President, Northrop Grumman.
  • Warden, who has served on the Catalyst Board for five years, was elected Chair effective April 1.
  • She became Chair, CEO and President of Northrop Grumman in 2019 after more than a decade at the company.

TIME Reveals the 2024 TIME100 List of the 100 Most Influential People in the World

Retrieved on: 
Wednesday, April 17, 2024
Gala, Booking.com, ABC, P&G, Woman, City, Verizon Communications, Partnership, Emmy Awards, LaToya Ruby Frazier, Host, Citigroup, Fantasia, TIME, Athlete, Kate Hudson, Television, Movement, Hulu, Merck, Letter, Film industry

NEW YORK, April 17, 2024 /PRNewswire/ -- Today, TIME reveals the 2024 TIME100, its annual list of the 100 most influential people in the world. The issue has 4 worldwide covers, each highlighting a member of the TIME100: singer-songwriter Dua Lipa, football quarterback Patrick Mahomes, actor Taraji P. Henson, and Yulia Navalnaya, a leader of Russia's opposition movement.

Key Points: 
  • See the full 2024 TIME100 list, tributes, videos and photos: time.com/time100
    See all four TIME100 covers: https://bit.ly/3VX2Oli
    Read the 2024 TIME100's editor's letter list: https://bit.ly/3JeuKJE
    The TIME100 list includes surprising pairings of the list members and the guest contributors TIME selects to write about them.
  • TIME Chief Executive Officer Jessica Sibley said: "The influence recognized on this year's TIME100 list of the world's most influential people spans industries and continents.
  • THE 2024 TIME100 SUMMIT AND GALA:
    TIME will celebrate the 2024 TIME100 list of the world's most influential people at the TIME100 Summit on April 24 and the TIME100 Gala on April 25 in New York City.
  • The fourth-annual TIME100 Summit will convene leaders from the global TIME100 community to spotlight solutions and encourage action toward a better world.

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

Retrieved on: 
Tuesday, April 16, 2024
Melanoma Research, Cancer, CMO, HKEX, Rutgers University, Learning, Biochemistry, Hospital, Mentorship, Oncology, Research, Hematology, IIC, Tufts Medical Center, Partnership, Pharmaceutical industry, NF-1, Molecular biology, Melanoma, Environment, Certification, Science, GSK, Patient, TMB, Faculty, Harvard Medical School, Pembrolizumab, Drug development, Merck, Massachusetts General Hospital, Autoimmunity, SAN, Dana–Farber Cancer Institute

Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.

Key Points: 
  • Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.
  • Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK.
  • Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology.
  • "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent.